Healthcare Technology — US PTAB Patent Cases
5 decisions indexed
Page 1 of 1 · 5 total
MIM Software Inc. et al. v.Progenics Pharmaceuticals, Inc. et al.
The PTAB denied MIM Software's IPR against Progenics Pharmaceuticals because the petition failed to provide adequate claim construction rationale. The Board found that Petitioner’s proposed constructions for 'risk indices' were too ambiguous and insufficiently supported by prior art.
MIM Software Inc. et al. v.Progenics Pharmaceuticals, Inc. et al.
The PTAB denied MIM Software's request to review claims in Progenics' medical image analysis patent. The denial was based on Petitioner's failure to provide a clear, single claim construction for key terms like 'risk map.'
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Zepp Health filed an IPR against Worcester Polytechnic Institute’s patent 10,653,362. The parties settled the dispute before a trial, and the Board terminated the proceeding, keeping the settlement confidential.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care challenged DexCom's CGM patents in an IPR, arguing the claims are obvious over prior art combining Yarger and Love. The Board granted institution after claim construction, finding a reasonable likelihood of unpatentability for at least one claim.
Abbott Diabetes Care Inc. et al. v.DexCom, Inc.
Abbott Diabetes Care successfully petitioned to institute IPR proceedings against DexCom for patent infringement related to remote patient monitoring and glucose technology. The Board found a reasonable likelihood of prevailing on multiple grounds, specifically finding that prior art combinations rendered key claims obvious under 35 U.S.C. § 103.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.